Michael Heffernan

Michael Thomas Heffernan was the founder of Clinical Studies Ltd. (1995), serving as President & Chief Executive Officer from 1995 to 1997.
Mr. Heffernan was the founder of Collegium Pharmaceutical, Inc. (2002), serving as Chairman from 2024 to 2025.
Mr. Heffernan was the founder of Onset Dermatologics LLC (2005), serving as President & Chief Executive Officer from 2005 to 2011.
Mr. Heffernan is the founder of PreCision Dermatology, Inc. (2010), serving as Director from 2010 to 2014.
Mr. Heffernan was the founder of Avenge Bio, Inc. (2019), serving as President, Chief Executive Officer & Director from 2019 to 2024.
Current jobs include Chairman at enGene Therapeutics, Inc. starting 2026, Chairman at NMD Pharma A starting 2023, Chairman at Indalo Therapeutics, Inc. starting 2019, Chairman at Avalo Therapeutics, Inc. starting 2025, Chairman at AAVantgarde Bio Srl, Lead Independent Director at Biohaven Ltd. starting 2020, Independent Director at Trevi Therapeutics, Inc. starting 2023, and Director at K36 Therapeutics, Inc. Former jobs include Chairman, President & Chief Executive Officer at Phymatrix Corp.
from 1999 to 2002, Chairman at Astellas Institute for Regenerative Medicine from 2013 to 2016, Chairman at CTx Operations, Inc., Chairman at Veloxis Pharmaceuticals A from 2016 to 2020, Director at TYRX, Inc., Director at Cornerstone BioPharma, Inc. in 2008, Independent Director at Akebia Therapeutics, Inc. from 2018 to 2022, Independent Director at Chiesi USA, Inc. from 2011 to 2014, Independent Director at Biohaven Pharmaceutical Holding Co. Ltd. from 2020 to 2021, Independent Director at Keryx Biopharmaceuticals, Inc. from 2016 to 2018, Independent Director at Synlogic, Inc. from 2020 to 2025, and Principal at Eli Lilly & Co. Education includes an undergraduate degree from the University of Connecticut, conferred in 1987.